strategies and tactics to leverage social and digital media in clinical research
DESCRIPTION
Inspire CEO Brian Loew presents "Strategies and Tactics to Leverage Social and Digital Media in Clinical Research," at the 2014 conference of the Drug Information Association (DIA) in San Diego, CA.TRANSCRIPT
Strategies and Tactics to Leverage Social and Digital Media in Clinical Research Brian Loew CEO Inspire [email protected] @brianloew
Disclaimer • The views and opinions expressed in the following PowerPoint
slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates, or any organization with which the presenter is employed or affiliated.
• These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the property of their respective owners.
2
About Inspire
Inspire (www.inspire.com) is the social network for health. Our online community of 500,000 patients and caregivers, organized by medical condition, helps industry connect with patients in order to accelerate and improve research.
Case study
In order to better understand Idiopathic Pulmonary Fibrosis patients, a pharmaceutical company partnered with Inspire.
About 70% of respondents said that “lack of therapies which make me feel better”
was a very troubling issue in trying to manage their IPF.
How would the following factors influence your decision to participate in a clinical trial? - 80% said that they saw as the benefit the promised comprehensive evaluation of their IPF and related conditions. - 41% said it was “neither a benefit or a drawback that they may be on a placebo. About 20% said the chance of being on placebo was a drawback to participating in a trial.
The benefits of social networks • In the best online communities — particularly
rare disease communities — patients are engaged, informed and passionate.
• Many patients want pathways to clinical research.
• Many patients want to be heard.
The voice of the IPF patient
“By you posting your experience, someone else who might brush off even looking into (certain IPF drugs) might change their mind because of your words and discuss it with their doctor.” Florida woman, 58
